2 weeks Ago By ABMN Staff
InMode Ltd. ( NASDAQ:INMD – Get Free Report ) has received an average rating of “Hold” from the six research firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company.
The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $22.40. Several equities research analysts have recently commented on the company.
Jefferies Financial Group cut InMode from a “buy” rating to a “hold” rating and cut their price target for the stock from $21.00 to $19.00 in a research note on Tuesday, July 23rd.
Canaccord Genuity Group cut their price target on InMode from $21.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, July 12th.
Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Thursday, July 11th. Finally, Barclays cut their price target on InMode from $33.00 to $29.
00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Get Our Latest Analysis on InMode InMode Trading Up 1.4 % InMode ( NASDAQ:INMD – Get Free Report ) last issued its quarterly earnings data on Thursday, August 1st.
The healthcare company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.
04). InMode had a net margin of 35.81% and a return on equity of 21.
00%. The firm had revenue of $102.60 million during the quarter, compared to analysts’ expectations of $104.
81 million. During the same quarter in the prior year, the firm posted $0.65 EPS.
InMode’s quarterly revenue was down 24.6% compared to the same quarter last year. As a group, research analysts predict that InMode will post 1.
63 earnings per share for the current year. Institutional Trading of InMode Several large investors have recently bought and sold shares of INMD. Principal Securities Inc.
acquired a new stake in InMode in the fourth quarter valued at $32,000. Norges Bank acquired a new stake in InMode in the fourth quarter valued at $8,890,000. D.
A. Davidson & CO. grew its holdings in InMode by 8.
1% in the fourth quarter. D.A.
Davidson & CO. now owns 31,405 shares of the healthcare company’s stock valued at $698,000 after purchasing an additional 2,360 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of InMode during the fourth quarter valued at $826,000.
Finally, Olympiad Research LP boosted its stake in shares of InMode by 39.2% during the fourth quarter. Olympiad Research LP now owns 11,575 shares of the healthcare company’s stock valued at $257,000 after acquiring an additional 3,257 shares during the last quarter.
Institutional investors and hedge funds own 68.04% of the company’s stock. About InMode ( Get Free Report InMode Ltd.
designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. Featured Articles Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.
com's FREE daily email newsletter ..
